This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prados, M. D. Articles by Kramer, S. Search for Related Content PubMed PubMed Citation Articles by Prados, M. D. Articles by Kramer, S. Social Bookmarking                            What's this?

Procarbazine, Lomustine, and Vincristine (PCV) Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine or PCV Adjuvant Chemotherapy

From the Department of Neurosurgery, University of California–San Francisco, San Francisco, CA.

Address reprint requests to Michael Prados, MD, University of California–San Francisco, Box 0372, San Francisco, CA 94143-0372; email pradosm{at}neuro.ucsf.edu

ABSTRACT

PURPOSE: To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy.

MATERIALS AND METHODS: The Radiation Therapy Oncology Group (RTOG) database was reviewed for patients with newly diagnosed AA treated according to protocols that included either BCNU or PCV adjuvant chemotherapy. All patients were treated with radiation therapy. The outcome analysis included overall survival, taking into account patient age, extent of resection, Karnofsky performance status (KPS), and treatment group (BCNU v PCV). Stratified and nonstratified Cox proportional hazards models were used, as well as an analysis using matched cases between the groups.

RESULTS: A total of 257 patients were treated with BCNU according to RTOG protocols 70-18, 83-02, and 90-06; 175 patients were treated with PCV according to RTOG protocol 94-04. All pretreatment characteristics except KPS were well balanced by treatment group; 61% of the BCNU group had a KPS of 90 to 100 compared with 73% of the PCV group (P = .0075). No statistically significant difference in survival was observed in any age group or by KPS or extent of surgery. The stratified analysis also showed no trends for improved survival by treatment group (P = .40). The Cox model identified only age, KPS, and extent of surgery as important variables influencing survival, not treatment group. Matching cases between groups using age, KPS, and surgery resulted in 133 matched pairs. No difference in survival was observed (P = .41). In a Cox model in which each matched pair is a strata, there was no difference between groups (P = .20).

CONCLUSION: Using this retrospective analysis, there does not seem to be any survival benefit to PCV chemotherapy. Future phase III studies for patients with AA may need to consider whether BCNU or PCV is used in the control arm.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm Central Nervous System Tumors Mayo Clin. Proc., October 1, 2007; 82(10): 1271 - 1286. [Abstract] [Full Text] [PDF]

				S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride Clin. Cancer Res., September 1, 2006; 12(17): 5174 - 5181. [Abstract] [Full Text] [PDF]

				A. A. Brandes, L. Nicolardi, A. Tosoni, M. Gardiman, P. Iuzzolino, C. Ghimenton, M. Reni, A. Rotilio, G. Sotti, and M. Ermani Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma Neuro-oncol, July 1, 2006; 8(3): 253 - 260. [Abstract] [Full Text] [PDF]

				F. M. Boyle, S. L. Eller, and S. A. Grossman Penetration of intra-arterially administered vincristine in experimental brain tumor Neuro-oncol, October 1, 2004; 6(4): 300 - 306. [Abstract] [PDF]

				J. K. Pueschel Integrative Tumor Board: Glioblastoma Multiforme: Neurooncology Integr Cancer Ther, June 1, 2004; 3(2): 151 - 152. [PDF]

				P. D. Brown, J. T. Wald, M. W. McDermott, G. S. Baumann, and T. F. Cloughesy Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. RadioGraphics, November 1, 2003; 23(6): 1591 - 1611. [Full Text] [PDF]

				V. A. Levin, K. R. Hess, A. Choucair, P. J. Flynn, K. A. Jaeckle, A. P. Kyritsis, W. K. A. Yung, M. D. Prados, J. M. Bruner, S. Ictech, et al. Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination {alpha}-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas Clin. Cancer Res., March 1, 2003; 9(3): 981 - 990. [Abstract] [Full Text] [PDF]

				M. C. Chamberlain, K. A. Jaeckle, S. Stenning, D. Thomas, and M. Brada Medical Research Council Adjuvant Trial in High-Grade Gliomas J. Clin. Oncol., October 1, 2001; 19(19): 3997 - 3999. [Full Text]

				L. M. DeAngelis Brain Tumors N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123. [Full Text] [PDF]